Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Acute Graft Versus Host Disease Pipeline Insight

DelveInsight’s, “Acute Graft-versus-Host Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Acute Graft-versus-Host Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Acute Graft-versus-Host Disease Understanding

Acute Graft-versus-Host Disease: Overview

Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplant (AHscT) is an immune triggered process, leading to profound immune dysregulation and organ dysfunction. The symptoms of Acute Graft-versus-host disease include maculopapular rash, hyperbilirubinemia with jaundice due to damage to the small bile ducts, leading to cholestasis; nausea, vomiting, and anorexia, watery or bloody diarrhea, and crampy abdominal pain. The diagnosis of acute GVHD relies on the assessment of target organs by means of clinical and laboratory analyses and biopsy. Acute GVHD is typically treated with a class of medication called glucocorticoids (steroids) and cyclosporine (immunosuppressive drugs).

 

"Acute Graft-versus-Host Disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Graft-versus-Host Disease pipeline landscape is provided which includes the disease overview and Acute Graft-versus-Host Disease treatment guidelines. The assessment part of the report embraces, in depth Acute Graft-versus-Host Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Graft-versus-Host Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Graft-versus-Host Disease R&D. The therapies under development are focused on novel approaches to treat/improve Acute Graft-versus-Host Disease.

Acute Graft-versus-Host Disease Emerging Drugs Chapters

This segment of the Acute Graft-versus-Host Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Acute Graft-versus-Host Disease Emerging Drugs

 

RGI-2001: Regimmune

RGI-2001 is a liposomal formulation of KRN7000, an alpha-galactosylceramide analog, embedded within the lipid bilayer to promote uptake by antigen presenting cells and presentation by CD1d. The drug is in Phase II clinical studies for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT).

 

MaaT013: MaaT Pharma

MaaT013 is a donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapy, containing Butycore, a group of bacterial species known to produce anti-inflammatory short-chain-fatty acids. The drug is in Phase III clinical studies for the treatment of ruxolitinib refractory GI-aGVHD.

Further product details are provided in the report……..

Acute Graft-versus-Host Disease: Therapeutic Assessment

This segment of the report provides insights about the different Acute Graft-versus-Host Disease drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Acute Graft-versus-Host Disease

There are approx. 20+ key companies which are developing the therapies for Acute Graft-versus-Host Disease. The companies which have their Acute Graft-versus-Host Disease drug candidates in the most advanced stage, i.e. Phase III include, MaaT Pharma.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Acute Graft-versus-Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Graft-versus-Host Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute Graft-versus-Host Disease therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Graft-versus-Host Disease drugs.

Acute Graft-versus-Host Disease Report Insights

  • Acute Graft-versus-Host Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Acute Graft-versus-Host Disease Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Acute Graft-versus-Host Disease drugs?
  • How many Acute Graft-versus-Host Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Graft-versus-Host Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Graft-versus-Host Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Graft-versus-Host Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Acute Graft-versus-Host Disease: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Acute Graft-versus-Host Disease – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

MaaT013: MaaT Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

RGI-2001: Regimmune

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

Itolizumab: Equillium

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Acute Graft-versus-Host Disease Key Companies

Acute Graft-versus-Host Disease Key Products

Acute Graft-versus-Host Disease- Unmet Needs

Acute Graft-versus-Host Disease- Market Drivers and Barriers

Acute Graft-versus-Host Disease- Future Perspectives and Conclusion

Acute Graft-versus-Host Disease Analyst Views

Appendix

List of Table

Table 1: Total Products for Acute Graft-versus-Host Disease

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Acute Graft-versus-Host Disease

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• OncoImmune (Merck)
• MaaT Pharma
• CSL Behring
• Equillium
• Roche
• Cellect Biotechnology
• Bristol-Myers Squibb
• Takeda
• Regimmune
• AltruBio
• Incyte Corporation
• Chia Tai Tianqing Pharmaceutical
• Kalytera Therapeutics
• ASC Therapeutics
• medac GmbH

 

Forward to Friend

Need A Quote